OR WAIT null SECS
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
San Diego-Immusol has begun a phase II clinical trial for its VitrenASE, a potential treatment for proliferative vitreoretinopathy (PVR) that could reduce the incidence of repeat retinal detachment after surgical repair.
Related Content: